Search Results
Results found for "Affiong Ika Oqua"
- Novel interaction between neurotrophic factor-α1/carboxypeptidase E and serotonin receptor, 5-HTR1E,
interaction between NFα1/CPE and 5-HTR1E and 125I NF-α1/CPE-binding studies demonstrated saturable, high-affinity
- Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!
Certificate of participation Learn the essentials: Measuring the pharmacologic activity of ligands (affinity
- Why “Displacement” Misleads You: Allosteric Binding Demystified
matter how much non-radioactive ligand you add, the binding curve levels off —because the receptor’s affinity
- Radioligands vs. Fluorescent Ligands: Binding Assays
. - Fluorescent probe design for specific targets: Not all targets have available high-affinity
- Dynamic GPCR activation revealed through time-resolved Cryo-EM
This interaction significantly increases the receptor’s affinity for GTP, allowing a detailed observation
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
the ligand engages the extracellular face of the receptor, providing an ‘address’ function: binding affinity , and by modifying these key points of contact it is possible not only to strongly increase binding affinity ligand analogs are engineered to optimize transmembrane domain providing significantly increased binding affinity to the isolation of several hundred candidate hits, enriched because they either bind with increased affinity proprietary multiplex synthesis technology, and then screened for pharmacological activity (receptor binding affinity
- Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor
Nanobody binding stabilizes G-protein-coupled receptors (GPCR) in a fully active state and modulates their affinity
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Terry's Corner : Stop Chasing Affinity and Start Reading the System In this week’s cornerstone Terry’
- Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes
However, blind assessments of ligand pose quality and affinity prediction have thus far not provided
- Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling
Gupte et al. utilized a systematic protein affinity strength modulation (SPASM) technique to show that
- 📰 GPCR Weekly News, June 19 to 25, 2023
Structural and Molecular Insights into GPCR Function Structure-Activity Relationship Study of the High-Affinity
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
LRRC8 volume-regulated anion channels through Gβγ signalling GPCR Binders, Drugs, and more PGE2 Binding Affinity
- 📰 GPCR Weekly News, May 22 to 28, 2023
Bioorthogonal Tethering Enhances Drug Fragment Affinity for G Protein-Coupled Receptors in Live Cells
- 📰 GPCR Weekly News, March 4 to 10, 2024
Pigment Activation Molecular dynamics-based identification of binding pathways and two distinct high-affinity
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
2024 What You’ll Learn during the four sessions: How to measure pharmacologic activity of ligands (affinity
- How Advanced GPCR Kinetics Sharpen Decision Making (and Save You Time)
Get functional—not just presence—readouts: Quantify affinity and kinetics where it matters.
- Dr. GPCR University registration is now open! Secure your spot now!
Materials Access to the private group Certificate Explore: Key metrics for assessing ligand pharmacology (affinity
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
latest insights delve into target residence time, revealing why kinetic persistence often trumps binding affinity
- 📰 GPCR Weekly News, June 24 to 30, 2024
activation of mTOR GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics A high-affinity
- 📰 GPCR Weekly News, February 6 to 12, 2023
Updates in GPCR Research Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity
- 📰 GPCR Weekly News, August 21 to 27, 2023
therapeutic targets in atopic diseases Methods & Updates in GPCR Research TrGPCR:GPCR-ligand Binding Affinity
- 📰 GPCR Weekly News, March 11 to 17, 2024
intercellular signaling Are there sex differences in oxytocin and vasopressin V1a receptors ligand binding affinities
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
Manchanda Y, ElEid L, Oqua AI, Ramchunder Z, Choi J, Shchepinova MM, et al.
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors Development of an Affinity-Based
- Unlocking the Future of Medicine: Advancements in GPCR Research
5th to 26th, 2024 Registrants will learn: Essentials of measuring pharmacologic activity of ligands (affinity
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
Mutations in target proteins can lead to decreased drug affinity and/or potency, rendering treatments
- 📰 GPCR Weekly News, April 24 to 30, 2023
Bioorthogonal Tethering Enhances Drug Fragment Affinity for G Protein-Coupled Receptors in Live Cells
- 📰 GPCR Weekly News, February 12 to 18, 2024
Broadens Biased Ligand Pharmacology Pharmacological characterization and radiolabeling of VUF15485, a high-affinity
- 📰 GPCR Weekly News, December 11 to 17, 2023
Function Using AlphaFold and Experimental Structures for the Prediction of the Structure and Binding Affinities
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
Mixed: A hybrid effect defined by variable affinities.
















